| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors.
|
Nat Med
|
2011
|
3.60
|
|
2
|
A simple method to cure established tumors by inflammatory killing of normal cells.
|
Nat Biotechnol
|
2004
|
2.39
|
|
3
|
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.
|
Clin Cancer Res
|
2008
|
2.18
|
|
4
|
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.
|
Clin Cancer Res
|
2008
|
1.91
|
|
5
|
Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy.
|
Nat Med
|
2007
|
1.74
|
|
6
|
Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.
|
Mol Ther
|
2009
|
1.72
|
|
7
|
Reovirus activates human dendritic cells to promote innate antitumor immunity.
|
J Immunol
|
2008
|
1.70
|
|
8
|
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.
|
Clin Cancer Res
|
2010
|
1.53
|
|
9
|
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.
|
Nat Biotechnol
|
2012
|
1.52
|
|
10
|
Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma.
|
Clin Cancer Res
|
2009
|
1.50
|
|
11
|
Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion.
|
Cancer Res
|
2002
|
1.42
|
|
12
|
Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer.
|
Cancer Res
|
2007
|
1.37
|
|
13
|
Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
|
Cancer Res
|
2005
|
1.35
|
|
14
|
Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer.
|
Cancer Res
|
2010
|
1.27
|
|
15
|
The biology of the sodium iodide symporter and its potential for targeted gene delivery.
|
Curr Cancer Drug Targets
|
2010
|
1.25
|
|
16
|
Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity.
|
Radiother Oncol
|
2009
|
1.25
|
|
17
|
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.
|
J Clin Invest
|
2010
|
1.22
|
|
18
|
Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas.
|
J Immunol
|
2006
|
1.20
|
|
19
|
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
|
BMC Cancer
|
2011
|
1.17
|
|
20
|
Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.
|
Clin Cancer Res
|
2009
|
1.17
|
|
21
|
Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells.
|
FEBS Lett
|
2007
|
1.16
|
|
22
|
Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse.
|
Mol Ther
|
2013
|
1.16
|
|
23
|
Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.
|
Hum Gene Ther
|
2011
|
1.16
|
|
24
|
Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.
|
Mol Ther
|
2008
|
1.16
|
|
25
|
VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.
|
Mol Ther
|
2010
|
1.15
|
|
26
|
Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
|
Hum Gene Ther
|
2010
|
1.15
|
|
27
|
Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas.
|
Cancer Res
|
2009
|
1.09
|
|
28
|
Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming.
|
Mol Cancer
|
2011
|
1.04
|
|
29
|
Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples.
|
Mod Pathol
|
2012
|
1.03
|
|
30
|
Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.
|
Clin Cancer Res
|
2007
|
1.02
|
|
31
|
Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus.
|
Mol Ther
|
2008
|
1.00
|
|
32
|
Exploiting synergies between radiation and oncolytic viruses.
|
Curr Opin Mol Ther
|
2008
|
0.99
|
|
33
|
Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
|
Mol Ther
|
2010
|
0.95
|
|
34
|
A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines.
|
Nat Med
|
2003
|
0.93
|
|
35
|
Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy.
|
Mol Ther
|
2011
|
0.92
|
|
36
|
Live viruses to treat cancer.
|
J R Soc Med
|
2013
|
0.89
|
|
37
|
Oncolytic viruses: time to compare, contrast, and combine? 5th international meeting on replicating oncolytic virus therapeutics. Banff, Alberta, Canada, 18-22 March 2009.
|
Mol Ther
|
2009
|
0.88
|
|
38
|
Differential effects of Paclitaxel on dendritic cell function.
|
BMC Immunol
|
2010
|
0.88
|
|
39
|
Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy.
|
Clin Cancer Res
|
2006
|
0.87
|
|
40
|
Cryopreserved dendritic cells for intratumoral immunotherapy do not require re-culture prior to human vaccination.
|
J Immunol Methods
|
2005
|
0.83
|
|
41
|
Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy.
|
Cancer Immunol Immunother
|
2007
|
0.83
|
|
42
|
The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysis.
|
Mol Ther
|
2010
|
0.82
|
|
43
|
Clinical grade OK432-activated dendritic cells: in vitro characterization and tracking during intralymphatic delivery.
|
J Immunother
|
2009
|
0.81
|
|
44
|
CD40-mediated death and cytokine secretion in colorectal cancer: a potential target for inflammatory tumour cell killing.
|
Int J Cancer
|
2007
|
0.80
|
|
45
|
Oncolytic viruses: do they have a role in anti-cancer therapy?
|
Clin Med Oncol
|
2008
|
0.78
|
|
46
|
The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.
|
Mol Ther
|
2012
|
0.78
|
|
47
|
An intravenous stimulus package for oncolytic virotherapy.
|
Mol Ther
|
2011
|
0.77
|
|
48
|
Future clinical potential of oncolytic virotherapy for pediatric CNS tumors.
|
CNS Oncol
|
2013
|
0.77
|
|
49
|
The hitchhiker's guide to virotherapy.
|
Oncotarget
|
2012
|
0.77
|
|
50
|
Talimogene laherparepvec in the treatment of melanoma.
|
Expert Opin Biol Ther
|
2015
|
0.76
|
|
51
|
Cancer immunotherapy.
|
N Engl J Med
|
2008
|
0.75
|
|
52
|
Adenovirally delivered enzyme prodrug therapy with herpes simplex virus-thymidine kinase in composite tissue free flaps shows therapeutic efficacy in rat models of glioma.
|
Plast Reconstr Surg
|
2015
|
0.75
|
|
53
|
International symposium on CTL and immunostimulation, Pamplona (Spain), October 26th and 27th 2010.
|
Cancer Immunol Immunother
|
2011
|
0.75
|